Bioporto AS (OCSE:BIOPOR) Current Accrued Expense : kr0.00 Mil (As of Mar. 2025)

View and export this data going back to 1993. Start your Free Trial

What is Bioporto AS Current Accrued Expense?

Bioporto AS's Current Accrued Expense for the quarter that ended in Mar. 2025 was kr0.00 Mil.

Bioporto AS Current Accrued Expense Historical Data

The historical data trend for Bioporto AS's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioporto AS Current Accrued Expense Chart

Bioporto AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Current Accrued Expense

Get a 7-Day Free Trial

Bioporto AS Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Current Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

Bioporto AS Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Bioporto AS Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Bioporto AS's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioporto AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Bioporto AS (OCSE:BIOPOR) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Tuborg Havnevej 15, Ground Floor, Hellerup, DNK, DK-2900

Website

https://www.bioporto.com

Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America.

Bioporto AS Headlines

No Headlines